Company intelligence / Profile preview

Legend Trading

Somerset, New Jersey, United Stateslegendtrading.com ↗

Ownership: Private
Employees: ~2500
Development stage: Commercial

Overview

CARVYKTI® (ciltacabtagene autoleucel), targeting BCMA for multiple myeloma, has demonstrated groundbreaking 5-year survival data at ASCO 2025. Several additional investigational agents are advancing through early-stage clinical trials targeting hematologic malignancies and solid tumors.

Therapeutic areas: Oncology
Modalities: Autologous CAR-T cell therapyAllogeneic CAR-T cell therapyGamma-delta T cell therapyNatural killer (NK) cell-based immunotherapy
Industry: Biotech

Partnerships

Janssen Pharmaceuticals / Johnson & Johnson – co-development/commercialization of ciltacabtagene autoleucel ("CARVYKTI")Academic collaborations with Philadelphia institutions anticipated due to new R&D site proximity

Beyond the preview

Go deeper on Legend Trading.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Legend Trading.

Explore the full profile